Investor Relations
Investor Relations
Corporate Profile
We are a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. Our programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies.
Change
Volume
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
